Tate currently serves as director of drug metabolism and pharmacokinetics at Regulus Therapeutics. Prior to joining Regulus, he was with Genalyte, Inc. pushing the frontiers in genomics, sequencing, and autoimmune diagnostics. At Regulus, he has advised and enabled the DMPK component of several research programs in disease area’s ranging from ADPKD, to diabetes, to hepatitis. Tate received his B.S. in chemistry from UC Santa Cruz, his Ph.D. in chemistry from UC Santa Barbara, and postdoctoral training from the University of Washington’s bioengineering department.